Picroside II
(Synonyms: 胡黄连苷II) 目录号 : GN10778
A flavonoid with diverse biological activities
Cas No.:39012-20-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EC50: 50 g/mL
PicrosideII is a major an iridoid glucoside isolated from Picrorhiza scrophulariiflora Pennell (Scrophulariaceae). Previous studies have shown that picroside II can protect cardiomyocytes against oxidative stress induced by hypoxia/ reoxygenation (H/R) injury.
In vitro: Pretreated cardiomyocytes with picroside II was found to inhibit LDH activity in culture media and increase cell viability in a dose-dependent manner. Such protective effect was accompanied with significant reduction of GSH contents and the activities of SOD and GSH-Px. Attenuated MDA and GSSG contents in response to H/R injury were observed as well. In addition, picroside II treatment also inhibited calcium accumulation and ROS production in cardiomyocytes. [1].
In vivo: A rat focal cerebral ischemic model was established, and picroside II were given intraperitoneally. Results indicated that the damage to the structures of the neurons and the blood brain barrier (BBB) in the cortex was more severe in the model group. In the picroside II treatment group, the neurological function, the morphology and ultrastructure of the neurons, and the BBB were improved. In addition, apoptotic cell number, cerebral infarct volume, EAR and pERK1/2 expression were decreased significantly compared to the model group [2].
Clinical trial: N/A
References:
[1] Meng FJ,Hou ZW,Li Y,Yang Y,Yu B. The protective effect of picroside II against hypoxia/reoxygenation injury in neonatal rat cardiomyocytes. Pharm Biol.2012 Oct;50(10):1226-32.
[2] Wang T,Zhao L,Guo Y,Zhang M,Pei H. Picroside II Inhibits Neuronal Apoptosis and Improves the Morphology and Structure of Brain Tissue following Cerebral Ischemic Injury in Rats. PLoS One.2015 Apr 30;10(4):e0124099.
| Cas No. | 39012-20-9 | SDF | |
| 别名 | 胡黄连苷II | ||
| 化学名 | [1a-(hydroxymethyl)-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bH-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxy-3-methoxybenzoate | ||
| Canonical SMILES | COC1=C(C=CC(=C1)C(=O)OC2C3C=COC(C3C4(C2O4)CO)OC5C(C(C(C(O5)CO)O)O)O)O | ||
| 分子式 | C23H28O13 | 分子量 | 512.46 |
| 溶解度 | ≥ 22.9mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9514 mL | 9.7569 mL | 19.5137 mL |
| 5 mM | 0.3903 mL | 1.9514 mL | 3.9027 mL |
| 10 mM | 0.1951 mL | 0.9757 mL | 1.9514 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet